/ /

  • linkedin
  • Increase Font
  • Sharebar

    Ocriplasmin promising in real-world vitreomacular traction trial


    Nice, France—Vitreomacular traction resolved in one-third of patients treated with ocriplasmin (Jetrea, ThromboGenics) within 28 days in a phase IV study of the new medication, according to Dr David Steel.

    Vitreomacular traction can reduce visual acuity and cause metamorphopsia and central field defect, he reminded the audience. It is believed that ocriplasmin treats this condition by cleaving fibronectin, laminin and collagen in the vitreous body and vitreoretinal interface, explained Dr Steel, a consultant ophthalmologist and vitreoretinal surgeon at Sunderland Eye infirmary in the United Kingdom. Dr Steel presented the finding at the European Society of Retina Specialists 15th EURETINA Congress.

    In two phase III controlled trials, ocriplasmin resolved vitreomacular adhesion and vitreomacular traction in 26.5% of cases within 28 days. By comparison, only 10.1% of cases treated with a placebo resolved in that amount of time (N. Engl. J. Med. 2012;367(7):606-615). Based on these trials, the US Food and Drug Administration approved ocriplasmin for vitreomacular traction and symptomatic vitreomacular holes in October 2012. The European Medicines Agency approved it in March 2012 for the treatment of vitreomacular traction, including cases associated with a macular hole of less than 400µm.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results